<description>&lt;div&gt;&lt;p&gt;&lt;a href="https://www.youtube.com/watch?v=N9YB9keYPXQ"&gt;&lt;strong&gt;Watch on YouTube&lt;br&gt;&lt;/strong&gt;&lt;/a&gt;&lt;br&gt;&lt;a href="https://www.voxmarkets.com/listings/MPAL:LN"&gt;MedPal AI Plc (AIM: MPAL)&lt;/a&gt;  has snapped up the Remedi pharmacy assets out of administration for less than half a million pounds — a deal that brings with it an NHS dispensing hub in Runcorn, a care home patient book that historically delivered over £10 million in annualised turnover, and a fleet of BD Rowa robotic dispensing kit. Founder and CEO Jason Drummond joins us to unpack the numbers, explain how the Swaffham reactivation playbook will be re-run at scale across the new patient book, and lay out the path to pharmacy-level EBITDA breakeven at 80,000 items a month — pencilled in for October or November this year. We get into the strategic logic of a north-south footprint, where the execution risks sit, and how today’s deal fits into the bigger MedPal story across &lt;a href="http://MedPal.clinic"&gt;MedPal.clinic&lt;/a&gt;, Health OS and the at-home blood test business.&lt;/p&gt;&lt;/div&gt;</description>

The Vox Markets Podcast

Vox Markets Podcast

2385: MedPal AI on the Road to Breakeven

APR 29, 20268 MIN
The Vox Markets Podcast

2385: MedPal AI on the Road to Breakeven

APR 29, 20268 MIN

Description

<div><p><a href="https://www.youtube.com/watch?v=N9YB9keYPXQ"><strong>Watch on YouTube<br></strong></a><br><a href="https://www.voxmarkets.com/listings/MPAL:LN">MedPal AI Plc (AIM: MPAL)</a>  has snapped up the Remedi pharmacy assets out of administration for less than half a million pounds — a deal that brings with it an NHS dispensing hub in Runcorn, a care home patient book that historically delivered over £10 million in annualised turnover, and a fleet of BD Rowa robotic dispensing kit. Founder and CEO Jason Drummond joins us to unpack the numbers, explain how the Swaffham reactivation playbook will be re-run at scale across the new patient book, and lay out the path to pharmacy-level EBITDA breakeven at 80,000 items a month — pencilled in for October or November this year. We get into the strategic logic of a north-south footprint, where the execution risks sit, and how today’s deal fits into the bigger MedPal story across <a href="http://MedPal.clinic">MedPal.clinic</a>, Health OS and the at-home blood test business.</p></div>